Wells Fargo & Company Imv Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.47 - $0.75 $107,263 - $171,165	228,220 Added 53.93%	651,406 $339,000
Q2 2022 Aug 12, 2022	SELL	$0.56 - $1.45 $7,513 - $19,454	-13,417 Reduced 3.07%	423,186 $279,000
Q1 2022 May 16, 2022	BUY	$1.07 - $1.5 $623 - $874	583 Added 0.13%	436,603 $629,000
Q4 2021 Feb 14, 2022	SELL	$1.22 - $1.78 $26,066 - $38,031	-21,366 Reduced 4.67%	436,020 $532,000
Q3 2021 Nov 15, 2021	BUY	$1.35 - $2.16 $316,102 - $505,764	234,150 Added 104.89%	457,386 $760,000
Q2 2021 Aug 16, 2021	SELL	$2.12 - $3.24 $97,768 - $149,419	-46,117 Reduced 17.12%	223,236 $486,000
Q1 2021 May 13, 2021	SELL	$2.92 - $4.41 $112,189 - $169,436	-38,421 Reduced 12.48%	269,353 $895,000
Q4 2020 Feb 09, 2021	SELL	$2.9 - $4.4 $177,085 - $268,681	-61,064 Reduced 16.56%	307,774 $948,000
Q3 2020 Nov 05, 2020	BUY	$2.87 - $5.95 $255,280 - $529,240	88,948 Added 31.78%	368,838 $1.64 Million
Q2 2020 Aug 13, 2020	BUY	$1.52 - $3.63 $386,300 - $922,546	254,145 Added 987.16%	279,890 $870,000
Q1 2020 May 14, 2020	BUY	$1.4 - $4.92 $36,043 - $126,665	25,745 New	25,745 $45,000

Ticker IMV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,452,200
Description
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is P...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.